Lite Strategy, Inc. (LITS)
0.9855
+0.01
(+0.52%)
USD |
NASDAQ |
Aug 31, 16:00
0.9758
-0.01
(-0.98%)
After-Hours: 20:00
Lite Strategy Total Long Term Debt (Quarterly) : 0.00 for March 31, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 10.62M |
| December 31, 2023 | 11.01M |
| September 30, 2023 | 11.33M |
| June 30, 2023 | 11.30M |
| March 31, 2023 | 11.67M |
| December 31, 2022 | 12.03M |
| September 30, 2022 | 12.38M |
| June 30, 2022 | 8.771M |
| March 31, 2022 | 9.211M |
| December 31, 2021 | 6.855M |
| September 30, 2021 | 7.115M |
| June 30, 2021 | 7.37M |
| March 31, 2021 | 7.608M |
| December 31, 2020 | 7.842M |
| September 30, 2020 | 8.072M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 0.157M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| Anika Therapeutics, Inc. | 23.32M |
| Savara, Inc. | 30.11M |